Lista de obras - Mario Salvi - Dominio Público Uruguay

A Comparative Analysis and Review of lysyl Residues Affected by Posttranslational Modifications

artículo científico

A new role for sphingosine: Up-regulation of Fam20C, the genuine casein kinase that phosphorylates secreted proteins.

artículo científico publicado en 2015

A quantitative method for assessing the degree of axial proptosis in relation to orbital tissue involvement in Graves' orbitopathy.

artículo científico publicado en 2013

A thyroid cytotoxic antibody that cross-reacts with an eye muscle cell surface antigen may be the cause of thyroid-associated ophthalmopathy

artículo científico publicado en 1988

Affinity purification of orbital membrane antigens for the study of the pathogenesis of Graves' ophthalmopathy

scientific article published on 01 May 1988

Antibodies in the serum of patients with autoimmune thyroid disorders react with a recombinant 98 amino acid fragment of a full length 64 kDa eye muscle membrane protein which is also expressed in the thyroid

artículo científico publicado en 1992

Antibodies reactive with an intracellular epitope of a recombinant 64 kDa thyroid and eye muscle protein in patients with thyroid autoimmunity and ophthalmopathy

scientific article published on 01 December 1993

B Cell Activating Factor (BAFF) and BAFF Receptor Expression in Autoimmune and Nonautoimmune Thyroid Diseases

artículo científico publicado en 2015

B cells in Graves' Orbitopathy: more than just a source of antibodies?

scientific article published on 04 December 2018

Beliefs, Knowledge, Implementation, and Integration of Evidence-Based Practice Among Primary Health Care Providers: Protocol for a Scoping Review.

artículo científico publicado en 2017

CK2 is a key regulator of SLC4A2-mediated Cl-/HCO3- exchange in human airway epithelia.

artículo científico publicado en 2017

COMPARISON OF METHIMAZOLE, METHIMAZOLE AND SODIUM IPODATE, AND METHIMAZOLE AND SATURATED SOLUTION OF POTASSIUM IODIDE IN THE EARLY TREATMENT OF HYPERTHYROID GRAVES’DISEASE

scientific article published on 01 March 1988

Cell-mediated immunity to orbital tissue antigens in thyroid-associated ophthalmopathy determined using the leukocyte procoagulant activity assay

artículo científico publicado en 1992

Classification and prediction of the progression of thyroid-associated ophthalmopathy by an artificial neural network.

artículo científico publicado en 2002

Combined immunosuppressants and less steroids in active graves' orbitopathy?

scientific article published on 09 January 2019

Combining micro-RNA and protein sequencing to detect robust biomarkers for Graves' disease and orbitopathy.

artículo científico publicado en 2018

Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO.

artículo científico publicado en 2008

Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone

artículo científico publicado en 2010

Design, validation and efficacy of bisubstrate inhibitors specifically affecting ecto-CK2 kinase activity.

artículo científico publicado en 2015

Dissecting the Role of K61/K59 Residue in VPS4 Functions.

artículo científico publicado en 2016

Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves' orbitopathy?

artículo científico publicado en 2017

Echographic diagnosis of pretibial myxedema in patients with autoimmune thyroid disease.

artículo científico publicado en 1994

Effect of sodium ipodate and iodide on free T4 and free T3 concentrations in patients with Graves' disease

artículo científico publicado en 1986

Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism

scientific article published on 01 April 1993

Effects of excess iodine administration on thyroid function in euthyroid patients with a previous episode of thyroid dysfunction induced by interferon-alpha treatment

artículo científico publicado en 1997

Efficacy and Safety of Three Different Cumulative Doses of Intravenous Methylprednisolone for Moderate to Severe and Active Graves' Orbitopathy

scientific article published on 04 October 2012

Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study.

artículo científico publicado en 2014

Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression

scientific article published on 01 April 2006

Evaluation of an enzyme-linked immunosorbent assay for the measurement of autoantibodies against eye muscle membrane antigens in Graves' ophthalmopathy

artículo científico publicado en 1986

Expulsion of an artificial eye in a patient with thyroid-associated ophthalmopathy and surgical anophthalmos

artículo científico publicado en 1999

Fully Automated Muscle Ultrasound Analysis (MUSA): Robust and Accurate Muscle Thickness Measurement.

artículo científico publicado en 2016

Future Research in Graves' Orbitopathy: From Priority Setting to Trial Design Through Patient and Public Involvement

artículo científico publicado en 2015

Graves' orbitopathy activation after radioactive iodine therapy with and without steroid prophylaxis

scientific article published on 30 June 2009

Graves' orbitopathy as a rare disease in Europe: a European Group on Graves' Orbitopathy (EUGOGO) position statement.

artículo científico publicado en 2017

Immunotherapy for Graves' ophthalmopathy

artículo científico publicado en 2014

Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease

artículo científico publicado en 1996

Isotype and immunoglobulin subclass distribution of eye muscle membrane reactive antibodies in the serum of patients with thyroid-associated ophthalmopathy as detected in Western blotting.

artículo científico publicado en 1991

MANAGEMENT OF ENDOCRINE DISEASE: Rituximab therapy for Graves' orbitopathy - lessons from randomized control trials

artículo científico publicado en 2017

Medical Treatment of Graves' Orbitopathy

artículo científico

Multiple granuloma faciale: a clinical finding from a dermoscopic point a view

scientific article published on 01 June 2018

Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial.

artículo científico publicado en 2018

Native gel electrophoresis and isoelectric focusing of a 64-kilodalton eye muscle protein shows that it is an important target for serum autoantibodies in patients with thyroid-associated ophthalmopathy and not expressed in other skeletal muscle

artículo científico publicado en 1995

Nature of 64 kDa eye muscle and thyroid membrane proteins and their significance in thyroid-associated ophthalmopathy--an hypothesis.

artículo científico publicado en 1993

Nature of a 64 kDa eye muscle membrane autoantigen as determined from immunoprecipitation and immunoblotting

artículo científico publicado en 1991

New immunomodulators in the treatment of Graves' ophthalmopathy

scientific article published on 15 April 2008

PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012.

artículo científico publicado en 2015

Pathogenesis of thyroid-associated ophthalmopathy

scientific article published on 01 January 1989

Pathogenesis of thyroid-associated ophthalmopathy: an autoimmune disorder of the eye muscle associated with Graves' hyperthyroidism and Hashimoto's thyroiditis

artículo científico publicado en 1993

Patients with endocrine ophthalmopathy not associated with overt thyroid disease have multiple thyroid immunological abnormalities.

artículo científico publicado en 1990

Prediction of the progression of thyroid-associated ophthalmopathy at first ophthalmologic examination: use of a neural network

artículo científico publicado en 2002

Predictive score for the development or progression of Graves' orbitopathy in patients with newly diagnosed Graves' hyperthyroidism

artículo científico publicado en 2018

Prevalence of antibodies reactive with a 64 kDa eye muscle membrane antigen in thyroid-associated ophthalmopathy

scientific article published on 01 January 1991

Proteomics perturbations promoted by the protein kinase CK2 inhibitor quinalizarin.

artículo científico publicado en 2015

Rituximab in the treatment of thyroid eye disease: science fiction?

artículo científico publicado en 2009

Rituximab induces distinct intraorbital and intrathyroidal effects in one patient satisfactorily treated for Graves' ophthalmopathy

artículo científico publicado en 2008

Rituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions.

artículo científico publicado en 2010

Role of the eye muscles in thyroid eye disease: identification of the principal autoantigens.

artículo científico publicado en 1998

Serum BAFF concentrations in patients with Graves' disease and orbitopathy before and after immunosuppressive therapy.

artículo científico publicado en 2012

Serum antibodies against the flavoprotein subunit of succinate dehydrogenase are sensitive markers of eye muscle autoimmunity in patients with Graves' hyperthyroidism

artículo científico publicado en 1999

Serum concentrations of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking

scientific article published on 01 August 2000

Significance of antibodies reactive with a 64 kDa eye muscle membrane antigen in patients with thyroid autoimmunity

artículo científico publicado en 1992

Significance of cytotoxic eye muscle antibodies in patients with thyroid-associated ophthalmopathy

artículo científico publicado en 1990

Small dose of rituximab for graves orbitopathy: new insights into the mechanism of action

artículo científico publicado en 2012

Statins may increase the risk of liver dysfunction in patients treated with steroids for active graves' orbitopathy.

artículo científico publicado en 2015

Step-down steroid-sparing therapy in active thyroid eye disease

artículo científico publicado en 2018

Structural and Dynamic Characterization of the Molecular Hub Early Region 1A (E1A) from Human Adenovirus.

artículo científico publicado en 2016

THERAPY OF ENDOCRINE DISEASE: Endocrine dilemma: management of Graves' orbitopathy

artículo científico publicado en 2016

Teprotumumab for Thyroid-Associated Ophthalmopathy.

artículo científico publicado en 2017

The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy

artículo científico publicado en 2016

The Impact of Central Obesity on Storage Luts and Urinary Incontinence After Prostatic Surgery.

artículo científico publicado en 2016

The acidophilic kinases PLK2 and PLK3: structure, substrate targeting and inhibition.

artículo científico publicado en 2018

The iodine perchlorate discharge test before and after one year of methimazole treatment of hyperthyroid Graves' disease

artículo científico publicado en 1994

The study of visual evoked potentials in patients with thyroid-associated ophthalmopathy identifies asymptomatic optic nerve involvement

scientific article published on 01 April 1997

The therapeutic outcome to intravenous steroid therapy for active Graves' orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor.

artículo científico publicado en 2013

Therapeutic Outcomes of High-Dose Intravenous Steroids in the Treatment of Dysthyroid Optic Neuropathy

artículo científico publicado en 2014

Thyroid ophthalmopathy

artículo científico publicado en 1994

Thyroid ultrasonography in patients with a previous episode of amiodarone induced thyrotoxicosis

artículo científico publicado en 1994

Thyroid-associated ophthalmopathy--a model for the association of organ-specific autoimmune disorders.

scientific article published on May 1991

Tocilizumab for thyroid eye disease

scientific article published on 27 November 2018

Tolterodine in the Treatment of Male LUTS.

artículo científico

Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study

artículo científico publicado en 2007

Treatment of pretibial myxedema with dexamethazone injected subcutaneously by mesotherapy needles

artículo científico publicado en 2013

Upper eyelid retraction in the absence of other evidence for progressive ophthalmopathy is associated with eye muscle autoantibodies

artículo científico publicado en 1995

Use of eye muscle antibody measurements to monitor response to plasmapheresis in patients with thyroid-associated ophthalmopathy

artículo científico publicado en 1993

Lista de obras de Mario Salvi

A Comparative Analysis and Review of lysyl Residues Affected by Posttranslational Modifications

A new role for sphingosine: Up-regulation of Fam20C, the genuine casein kinase that phosphorylates secreted proteins.

A quantitative method for assessing the degree of axial proptosis in relation to orbital tissue involvement in Graves' orbitopathy.

A thyroid cytotoxic antibody that cross-reacts with an eye muscle cell surface antigen may be the cause of thyroid-associated ophthalmopathy

Affinity purification of orbital membrane antigens for the study of the pathogenesis of Graves' ophthalmopathy

Antibodies in the serum of patients with autoimmune thyroid disorders react with a recombinant 98 amino acid fragment of a full length 64 kDa eye muscle membrane protein which is also expressed in the thyroid

Antibodies reactive with an intracellular epitope of a recombinant 64 kDa thyroid and eye muscle protein in patients with thyroid autoimmunity and ophthalmopathy

B Cell Activating Factor (BAFF) and BAFF Receptor Expression in Autoimmune and Nonautoimmune Thyroid Diseases

B cells in Graves' Orbitopathy: more than just a source of antibodies?

Beliefs, Knowledge, Implementation, and Integration of Evidence-Based Practice Among Primary Health Care Providers: Protocol for a Scoping Review.

CK2 is a key regulator of SLC4A2-mediated Cl-/HCO3- exchange in human airway epithelia.

COMPARISON OF METHIMAZOLE, METHIMAZOLE AND SODIUM IPODATE, AND METHIMAZOLE AND SATURATED SOLUTION OF POTASSIUM IODIDE IN THE EARLY TREATMENT OF HYPERTHYROID GRAVES’DISEASE

Cell-mediated immunity to orbital tissue antigens in thyroid-associated ophthalmopathy determined using the leukocyte procoagulant activity assay

Classification and prediction of the progression of thyroid-associated ophthalmopathy by an artificial neural network.

Combined immunosuppressants and less steroids in active graves' orbitopathy?

Combining micro-RNA and protein sequencing to detect robust biomarkers for Graves' disease and orbitopathy.

Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO.

Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone

Design, validation and efficacy of bisubstrate inhibitors specifically affecting ecto-CK2 kinase activity.

Dissecting the Role of K61/K59 Residue in VPS4 Functions.

Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves' orbitopathy?

Echographic diagnosis of pretibial myxedema in patients with autoimmune thyroid disease.

Effect of sodium ipodate and iodide on free T4 and free T3 concentrations in patients with Graves' disease

Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism

Effects of excess iodine administration on thyroid function in euthyroid patients with a previous episode of thyroid dysfunction induced by interferon-alpha treatment

Efficacy and Safety of Three Different Cumulative Doses of Intravenous Methylprednisolone for Moderate to Severe and Active Graves' Orbitopathy

Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study.

Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression

Evaluation of an enzyme-linked immunosorbent assay for the measurement of autoantibodies against eye muscle membrane antigens in Graves' ophthalmopathy

Expulsion of an artificial eye in a patient with thyroid-associated ophthalmopathy and surgical anophthalmos

Fully Automated Muscle Ultrasound Analysis (MUSA): Robust and Accurate Muscle Thickness Measurement.

Future Research in Graves' Orbitopathy: From Priority Setting to Trial Design Through Patient and Public Involvement

Graves' orbitopathy activation after radioactive iodine therapy with and without steroid prophylaxis

Graves' orbitopathy as a rare disease in Europe: a European Group on Graves' Orbitopathy (EUGOGO) position statement.

Immunotherapy for Graves' ophthalmopathy

Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease

Isotype and immunoglobulin subclass distribution of eye muscle membrane reactive antibodies in the serum of patients with thyroid-associated ophthalmopathy as detected in Western blotting.

MANAGEMENT OF ENDOCRINE DISEASE: Rituximab therapy for Graves' orbitopathy - lessons from randomized control trials

Medical Treatment of Graves' Orbitopathy

Multiple granuloma faciale: a clinical finding from a dermoscopic point a view

Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial.

Native gel electrophoresis and isoelectric focusing of a 64-kilodalton eye muscle protein shows that it is an important target for serum autoantibodies in patients with thyroid-associated ophthalmopathy and not expressed in other skeletal muscle

Nature of 64 kDa eye muscle and thyroid membrane proteins and their significance in thyroid-associated ophthalmopathy--an hypothesis.

Nature of a 64 kDa eye muscle membrane autoantigen as determined from immunoprecipitation and immunoblotting

New immunomodulators in the treatment of Graves' ophthalmopathy

PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012.

Pathogenesis of thyroid-associated ophthalmopathy

Pathogenesis of thyroid-associated ophthalmopathy: an autoimmune disorder of the eye muscle associated with Graves' hyperthyroidism and Hashimoto's thyroiditis

Patients with endocrine ophthalmopathy not associated with overt thyroid disease have multiple thyroid immunological abnormalities.

Prediction of the progression of thyroid-associated ophthalmopathy at first ophthalmologic examination: use of a neural network

Predictive score for the development or progression of Graves' orbitopathy in patients with newly diagnosed Graves' hyperthyroidism

Prevalence of antibodies reactive with a 64 kDa eye muscle membrane antigen in thyroid-associated ophthalmopathy

Proteomics perturbations promoted by the protein kinase CK2 inhibitor quinalizarin.

Rituximab in the treatment of thyroid eye disease: science fiction?

Rituximab induces distinct intraorbital and intrathyroidal effects in one patient satisfactorily treated for Graves' ophthalmopathy

Rituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions.

Role of the eye muscles in thyroid eye disease: identification of the principal autoantigens.

Serum BAFF concentrations in patients with Graves' disease and orbitopathy before and after immunosuppressive therapy.

Serum antibodies against the flavoprotein subunit of succinate dehydrogenase are sensitive markers of eye muscle autoimmunity in patients with Graves' hyperthyroidism

Serum concentrations of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking

Significance of antibodies reactive with a 64 kDa eye muscle membrane antigen in patients with thyroid autoimmunity

Significance of cytotoxic eye muscle antibodies in patients with thyroid-associated ophthalmopathy

Small dose of rituximab for graves orbitopathy: new insights into the mechanism of action

Statins may increase the risk of liver dysfunction in patients treated with steroids for active graves' orbitopathy.

Step-down steroid-sparing therapy in active thyroid eye disease

Structural and Dynamic Characterization of the Molecular Hub Early Region 1A (E1A) from Human Adenovirus.

THERAPY OF ENDOCRINE DISEASE: Endocrine dilemma: management of Graves' orbitopathy

Teprotumumab for Thyroid-Associated Ophthalmopathy.

The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy

The Impact of Central Obesity on Storage Luts and Urinary Incontinence After Prostatic Surgery.

The acidophilic kinases PLK2 and PLK3: structure, substrate targeting and inhibition.

The iodine perchlorate discharge test before and after one year of methimazole treatment of hyperthyroid Graves' disease

The study of visual evoked potentials in patients with thyroid-associated ophthalmopathy identifies asymptomatic optic nerve involvement

The therapeutic outcome to intravenous steroid therapy for active Graves' orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor.

Therapeutic Outcomes of High-Dose Intravenous Steroids in the Treatment of Dysthyroid Optic Neuropathy

Thyroid ophthalmopathy

Thyroid ultrasonography in patients with a previous episode of amiodarone induced thyrotoxicosis

Thyroid-associated ophthalmopathy--a model for the association of organ-specific autoimmune disorders.

Tocilizumab for thyroid eye disease